Lilly drug cuts risk of disease progression or death by 80% in trial
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
Subscribe To Our Newsletter & Stay Updated